The Trump administration is preparing to launch a new investigation under Section 301 of the Trade Act of 1974 to determine ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's ...

For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $407.9, denoting a -1.05% move from the preceding trading day.

Vertex Pharmaceuticals Incorporated has recently witnessed a notable change in its stock holdings, with Aberdeen Group plc ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals has been a clear winner in the pharmaceutical sector. Over the past two decades, this powerhouse has ...

Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...

Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital ...

Investors have feared that U.S. import tariffs may hurt companies’ earnings growth -- and weigh on stock performance. The following two players not only offer safety from that risk but also give you ...

Investing.com -- Stoke Therapeutics (NASDAQ:STOK) stock rose 7% Monday after the company announced the appointment of Ian F. Smith as its permanent Chief Executive Officer.

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.